不同剂量Galcanezumab对比安慰剂预防发作性偏头痛的随机临床试验
该随机临床试验在美国37家诊所纳入410例发作性偏头痛患者,每月皮下注射Galcanezumab 5、50、120或300 mg或安慰剂,治疗3个月。主要终点为随机化后9至12周偏头痛天数较基线的平均变化,结果显示120 mg和300 mg剂量有效,所有剂量安全且耐受良好。
要点
- Galcanezumab 120 mg和300 mg每月皮下注射可有效预防发作性偏头痛。
- 常见不良事件包括注射部位疼痛、上呼吸道感染、鼻咽炎、痛经和恶心。
- 所有测试剂量在发作性偏头痛预防中均安全且耐受良好。
核心结论
- 每月皮下注射Galcanezumab 120 mg和300 mg对偏头痛预防显示出疗效,支持在更大规模III期研究中进一步开发。
- 所有剂量在发作性偏头痛的预防治疗中安全且耐受良好。
研究设计与样本
- 随机临床试验在美国37名执业医师的诊所进行,时间从2014年7月7日至2015年8月19日。
- 共评估936例患者,410例随机接受安慰剂或Galcanezumab 5、50、120或300 mg每月皮下注射,治疗3个月。
- 分析基于意向治疗人群,包括所有随机化并至少接受1剂研究药物的患者。
主要发现
- 主要终点为随机化后9至12周偏头痛天数较基线的平均变化,Galcanezumab 120 mg组较安慰剂组显著减少偏头痛天数(99.6%后验概率 -4.8天;90% BCI,-5.4至-4.2天 vs 95%优效性阈值[贝叶斯分析] -3.7天;90% BCI,-4.1至-3.2天)。
- 至少1个Galcanezumab剂量组中5%或以上患者报告且比安慰剂组更频繁的不良事件包括注射部位疼痛、上呼吸道感染、鼻咽炎、痛经和恶心。
关键数值与推荐
- 入组标准:年龄18-65岁,每月4-14个偏头痛天数,偏头痛起病年龄小于50岁。
- 主要终点优效性阈值(贝叶斯分析)为-3.7天(90% BCI,-4.1至-3.2天)。
临床怎么用
- 对于发作性偏头痛预防,可考虑每月皮下注射Galcanezumab 120 mg或300 mg。
- 治疗期间允许按需使用短期偏头痛治疗药物,但阿片类或巴比妥类药物除外。
局限性
- 研究为短期(3个月治疗期)试验,长期疗效和安全性需进一步研究。
- 样本量有限(410例随机化),需更大规模III期研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE: To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted in the United States (July 7, 2014, to August 19, 2015) in clinics of 37 licensed physicians with a specialty including, but not limited to, psychiatry, neurology, internal medicine, and primary care. Subcutaneous injections of galcanezumab, 5, 50, 120, or 300 mg, or placebo were given monthly during the 3-month treatment period. A total of 936 patients were assessed; 526 did not meet study entry or baseline criteria and 410 patients were randomly assigned to receive placebo or galcanezumab. Analyses were conducted on an intent-to-treat population, which included all patients who were randomized and received at least 1 dose of study drug. INTERVENTIONS: Short-term migraine treatments were allowed as needed except for opioids or barbiturates. MAIN OUTCOMES AND MEASURES: To determine if at least 1 of the 4 doses of galcanezumab tested was superior to placebo for migraine prevention measured by the mean change from baseline in the number of migraine headache days 9 weeks to 12 weeks after randomization. RESULTS: Of the 936 patients assessed, 410 met entry criteria (aged 18-65 years with 4-14 migraine headache days per month and migraine onset prior to age 50 years) and were randomized to receive placebo or galcanezumab. For the primary end point, galcanezumab, 120 mg, significantly reduced migraine headache days compared with placebo (99.6% posterior probability -4.8 days; 90% BCI, -5.4 to -4.2 days vs 95% superiority threshold [Bayesian analysis] -3.7 days; 90% BCI, -4.1 to -3.2 days). Adverse events reported by 5% or more of patients in at least 1 galcanezumab dose group and more frequently than placebo included injection-site pain, upper respiratory tract infection, nasopharyngitis, dysmenorrhea, and nausea. CONCLUSIONS AND RELEVANCE: Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. All dosages were safe and well tolerated for the preventive treatment of episodic migraine. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02163993.
引用
- Skljarevski V, Oakes TM, Zhang Q, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29255900. doi:10.1001/jamaneurol.2017.3859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。